Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Eli Lilly & Co. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Profitability Ratios
- Analysis of Solvency Ratios
- Dividend Discount Model (DDM)
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Eli Lilly & Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The investment activity ratios exhibit varied trends over the observed period. Generally, a slight decline in asset utilization efficiency is apparent, though with some quarterly fluctuations. The equity turnover ratio demonstrates more volatility, with a recent upward movement.
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio began at 3.22 and generally decreased to 2.64 by March 31, 2023. Subsequent quarters showed some recovery, peaking at 2.70 in September 2023, but ultimately settled at 2.64 by December 2025. This suggests a decreasing efficiency in generating revenue from fixed assets, followed by a period of stabilization. The decline may indicate overinvestment in fixed assets or slower sales growth relative to those assets.
- Total Asset Turnover
- The total asset turnover ratio showed a consistent decline from 0.62 in the first three quarters of 2022 to 0.52 in March 2023. A modest recovery occurred through September 2023 (0.55), followed by a dip to 0.53 in December 2023. The ratio then increased to 0.58 by December 2025. This pattern indicates a decreasing ability to generate sales from all assets, followed by a recent improvement. The initial decline could be attributed to increased asset holdings without a corresponding increase in sales.
- Equity Turnover
- The equity turnover ratio experienced significant fluctuations. It rose from 3.14 in March 2022 to 3.40 in June 2022, then decreased to 2.68 by December 2022. A subsequent decline to 2.47 in March 2023 was followed by a substantial increase, reaching 3.17 in December 2023. The ratio then decreased to 2.46 by December 2025. This volatility suggests a changing relationship between sales and equity financing, potentially influenced by share repurchases, dividend policies, or changes in profitability. The recent decline warrants further investigation.
Overall, the observed trends suggest a period of decreasing asset utilization efficiency, particularly concerning fixed assets and total assets, followed by a recent stabilization or slight improvement. The equity turnover ratio’s volatility requires further scrutiny to understand the underlying drivers of its fluctuations.
Net Fixed Asset Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Revenue | |||||||||||||||||||||
| Property and equipment, net of accumulated depreciation | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Net fixed asset turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Net fixed asset turnover
= (RevenueQ4 2025
+ RevenueQ3 2025
+ RevenueQ2 2025
+ RevenueQ1 2025)
÷ Property and equipment, net of accumulated depreciation
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The net fixed asset turnover ratio exhibits a generally declining trend over the observed period, although with some fluctuations. Initially, the ratio remained relatively stable between 3.14 and 3.22 from March 2022 to September 2022. A more pronounced decrease began in December 2022, falling to 2.81, and continued through March 2023, reaching a low of 2.63. The ratio experienced a slight recovery in the subsequent quarters, peaking at 2.70 in September 2023, but remained below the levels seen in the earlier part of the period. From September 2023 through December 2025, the ratio fluctuated within a narrow range of 2.53 to 2.66, indicating a stabilization at a lower level than previously observed.
- Overall Trend
- The overall trend indicates decreasing efficiency in generating revenue from fixed assets. While the ratio stabilized in the most recent quarters, it remains significantly lower than the figures recorded in 2022. This suggests that the company is either utilizing its fixed assets less effectively or is requiring a greater investment in fixed assets to generate the same level of revenue.
- Revenue Impact
- Revenue demonstrated an increasing trend overall, particularly with substantial growth observed from March 2024 onwards. However, the growth in revenue did not translate into a corresponding increase in the net fixed asset turnover ratio, suggesting that the increase in revenue is driven by factors other than more efficient utilization of existing fixed assets. The substantial revenue increases in the later periods appear to be offset by even larger increases in property, plant, and equipment.
- Fixed Asset Investment
- Property and equipment, net of accumulated depreciation, consistently increased throughout the period. This continuous investment in fixed assets, coupled with the declining turnover ratio, suggests that the company is actively expanding its asset base, potentially in anticipation of future growth, or to maintain its competitive position. However, the current asset base is not being utilized as efficiently as it was previously.
- Recent Stabilization
- The stabilization of the ratio between 2.53 and 2.66 in the latter part of the period may indicate that the company’s investment strategy is beginning to yield results, or that the rate of asset expansion is moderating. Further monitoring is needed to determine if this stabilization represents a long-term trend or a temporary pause in the decline.
Total Asset Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Revenue | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Total asset turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Total asset turnover
= (RevenueQ4 2025
+ RevenueQ3 2025
+ RevenueQ2 2025
+ RevenueQ1 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The total asset turnover ratio for the analyzed period demonstrates a generally stable, albeit slightly declining, trend with some fluctuation. Initially, the ratio held steady before exhibiting a noticeable decrease and subsequent modest recovery.
- Initial Stability (Mar 31, 2022 - Dec 31, 2022)
- The total asset turnover ratio began the period at 0.62 for both the March and June quarters of 2022. It remained at this level for two consecutive quarters before decreasing to 0.58 by the end of 2022, indicating a slight reduction in revenue generated per dollar of assets.
- Decline and Initial Recovery (Mar 31, 2023 - Dec 31, 2023)
- The ratio continued its downward trajectory in the first quarter of 2023, reaching a low of 0.52. A modest recovery followed, with the ratio increasing to 0.54 and 0.55 in the subsequent two quarters. However, it decreased slightly to 0.53 by the end of 2023, suggesting the initial recovery was not fully sustained.
- Fluctuation and Recent Increase (Mar 31, 2024 - Dec 31, 2025)
- The ratio experienced further fluctuation, moving from 0.56 in the first quarter of 2024 to 0.54 in the second. It then increased to 0.57 and 0.55 in the following quarters. The most recent quarters show a more pronounced upward trend, with the ratio reaching 0.53, 0.52, and finally 0.58 by the end of 2025. This represents the highest value observed in the analyzed period.
- Overall Trend
- Despite the fluctuations, the overall trend suggests a slight decrease in asset turnover from 2022 to 2023, followed by a period of stabilization and a recent increase towards the end of the analyzed timeframe. The increase in the most recent quarter indicates a potentially improving efficiency in asset utilization.
The observed changes in the total asset turnover ratio warrant further investigation to determine the underlying drivers, such as changes in sales strategies, asset management practices, or industry dynamics. The recent increase is a positive sign, but continued monitoring is necessary to assess its sustainability.
Equity Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Revenue | |||||||||||||||||||||
| Total Eli Lilly and Company shareholders’ equity | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Equity turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Equity turnover
= (RevenueQ4 2025
+ RevenueQ3 2025
+ RevenueQ2 2025
+ RevenueQ1 2025)
÷ Total Eli Lilly and Company shareholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The equity turnover ratio for the analyzed period demonstrates fluctuations, generally remaining within a relatively narrow range. Initial values indicate a moderate level of equity utilization, followed by a period of decline and subsequent stabilization before a recent downward shift.
- Overall Trend
- From March 31, 2022, to December 31, 2022, the equity turnover ratio experienced a decreasing trend, moving from 3.14 to 2.68. This suggests a diminishing ability to generate revenue from each dollar of shareholder equity during this timeframe. A subsequent recovery occurred through December 31, 2023, peaking at 3.17, indicating improved efficiency in utilizing equity to generate sales. However, the ratio has since declined, reaching 2.46 by December 31, 2025.
- Peak and Trough Values
- The highest recorded equity turnover ratio was 3.40, observed in June 30, 2022. The lowest value was 2.46, recorded on December 31, 2025. The difference between these values highlights the variability in the company’s efficiency in converting equity financing into revenue.
- Recent Performance (2024-2025)
- The period from March 31, 2024, through December 31, 2025, shows a consistent downward trend in the equity turnover ratio. Starting at 2.80, the ratio decreased to 2.46. This suggests a potential weakening in the relationship between equity and revenue generation in the most recent quarters. This decline warrants further investigation to determine the underlying causes, such as changes in asset utilization or revenue generation strategies.
- Relationship to Revenue
- While the equity turnover ratio decreased in the latter part of the analyzed period, revenue generally increased. This suggests that revenue growth is not solely dependent on increased equity turnover, and other factors, such as improved sales efficiency or increased market demand, may be contributing to revenue gains. However, the decreasing equity turnover alongside increasing revenue could also indicate a growing reliance on debt financing or other non-equity sources of funding.
In summary, the equity turnover ratio exhibits cyclical behavior with a recent downward trend. While revenue has continued to grow, the decreasing ratio suggests a potential shift in the company’s financial dynamics and warrants continued monitoring.